Please login to the form below

Not currently logged in
Email:
Password:

Lilly launches innovation platform

Eli Lilly & Company has launched a drug discovery platform that aims to help boost the pharmaceutical company's R&D partnerships through a unique website

Eli Lilly & Company has launched a drug discovery platform focusing on developing treatments in areas of unmet medical need.

The platform is supported by the website openinnovation.Lilly.com through which scientists can submit molecules for Lilly to test to evaluate for further development. Data reports are then provided for them.

In the case of cancer, endocrine, cardiovascular and neuroscience screenings, Lilly said it would retain first rights to negotiate an agreement with the submitter in return for providing the data.

The platform itself consists of three components, the first of which screens submitted molecules for their potential to interact with known disease targets.

The second component then screens the molecules again in order to identify potential new medicines acting by novel mechanisms or pathways.

The final component screens molecules specifically for their potential as therapies for MDR-TB - a form of tuberculosis (TB) that is resistant to some TB medicines.

Dr Jan Lundberg, executive vice president, science and technology, and president, Lilly Research Laboratories, explained that partnership programmes were an increasing priority for Lilly in developing new products.

He said: "We recognise that there are many untapped sources of ideas and molecules outside of Lilly that would otherwise go unnoticed without initiatives like this one that advance science."

27th September 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...